Hikma Pharmaceuticals Public annual return on assets (roa)
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Return on Assets (ROA) Growth & History (HIK)
Hikma Pharmaceuticals Public's return on assets (roa) was 7.53% for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 7.53% | +0.16 pp |
| 2024 | 2024-12-31 | 7.38% | +3.18 pp |
| 2023 | 2023-12-31 | 4.20% | −0.12 pp |
| 2022 | 2022-12-31 | 4.32% | −5.55 pp |
| 2021 | 2021-12-31 | 9.87% | — |
Hikma Pharmaceuticals Public return on assets (roa) trends
Between the periods ended 2021-12-31 and 2025-12-31, Hikma Pharmaceuticals Public's return on assets (roa) decreased from 9.87% to 7.53%, a change of −2.34 percentage points.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...